# SWOG S1605 (NCT02844816)

> Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: BCG-unresponsive high-risk non-muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02844816
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Recurrent Bladder Urothelial Carcinoma; Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7; Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7; Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
- Interventions: Atezolizumab
- Enrollment: 172
- Primary outcome: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS)
- Primary outcome: Event-free Survival (EFS)

## Indexed commentary on SWOG S1605 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 9
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=swog-s1605-nct02844816

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02844816", "email": "<work email>"}; the inbox owner confirms by the emailed link.